E Global Investing Friday File

Novartis reported 72% and 39.1% response rates in treatment-naive and new patients in its trial for patients with advanced MET exon14 skipping non-small cell lung cancer treated with Cabozantinib. It also reported at the European Oncology gathering on liver cancer treatment with Netter-1 lutathera which also showed significant improvement in progression-free survival – but with no numbers.

*Roche sub Genentech got US FDA okay to add two new label uses for its Rituxin, against rare vasculitis variations. Its stock rose 2.7%.


*German utility E.On SE, EONGY, set up a jv to charge electric vehicles with Seas-NVE. It rose 2.53%.

*Indian solar and renewable energy firm Azure Power rose 0.5% after the market adjusted the outlook over its capital increase, made in a hurry because of local factors. We think that the new shareholders being the same as the old is a mark of confidence in AZRE management and its decision to diversify into other renewables from solar energy.


*Vodafone has been rising nicely despite a sell call by Raymond James brokerage. VOD is a cellphone operator in Britain, Europe, and India.

*Naspers of South Africa first fall here today before recovering as its 31% owned Tencent of Hong Kong rose fractionally. NPSNY is so much bigger than its mere stake in TCEHY , but the market doesn't understand this.


*Orocobre of Australia rose 1.8% in Canada trading. It mines lithium in Argentina and its homeland and also controls a startup Canadian miner in Argentina which reported on its drill tests yesterday. Presumably, the information was good.

*Swedish Autoliv is close to a 12-mo low after a down rating to neutral by Citigroup.


*Mexican Reit Fibra Uno (FBASF) created a jv with WeWork, operator of offices for free-lancers, for Mexico. It will initially offer the service 50,000 square meters of workspace which will double to 100,000 by the year 2021.

1 2
View single page >> |

Disclosure: None. Subscribe to Global-Investing for more updates.

How did you like this article? Let us know so we can better customize your reading experience. Users' ratings are only visible to themselves.


Leave a comment to automatically be entered into our contest to win a free Echo Show.
Kate Monroe 10 months ago Member's comment

So do you think this would be a good place to get into Bioline? Are you averaging down now? Or do you think the stock got bid up too far on too-optimistic expectations and is now settling down?

George Lipton 10 months ago Member's comment

Sounds like it to me.